Terence Flynn
Stock Analyst at Morgan Stanley
(4.05)
# 453
Out of 4,778 analysts
178
Total ratings
56.12%
Success rate
9.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Equal-Weight | $48 → $12 | $8.13 | +47.60% | 8 | Mar 13, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $145 → $139 | $97.16 | +43.07% | 2 | Mar 11, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $69 → $63 | $29.86 | +110.98% | 2 | Mar 7, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $36 → $25 | $8.40 | +197.62% | 5 | Feb 18, 2025 | |
| OGN Organon & Co. | Maintains: Equal-Weight | $17 → $16 | $14.72 | +8.70% | 8 | Feb 14, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Underweight | $30 → $32 | $40.88 | -21.72% | 7 | Feb 14, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $113 → $106 | $87.85 | +20.66% | 16 | Feb 5, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $224 → $239 | $201.31 | +18.72% | 14 | Feb 3, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $16 → $17 | $12.59 | +35.03% | 4 | Feb 3, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Equal-Weight | $56 → $11 | $8.74 | +25.86% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $175 → $163 | $161.04 | +1.22% | 19 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $39 | $59.20 | -34.12% | 10 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $31 | $25.55 | +21.33% | 17 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $20.28 | +481.85% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,106 | $852.34 | +29.76% | 18 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $3.99 | +802.26% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $51 | $33.76 | +51.07% | 11 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $310 → $303 | $306.76 | -1.23% | 5 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $310 → $321 | $316.57 | +1.40% | 8 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $121 → $168 | $93.15 | +80.35% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.17 | +268.66% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $139.18 | +213.26% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $281.02 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.34 | - | 1 | Jul 21, 2017 |
Arvinas
Mar 13, 2025
Maintains: Equal-Weight
Price Target: $48 → $12
Current: $8.13
Upside: +47.60%
BioNTech SE
Mar 11, 2025
Maintains: Overweight
Price Target: $145 → $139
Current: $97.16
Upside: +43.07%
Biohaven
Mar 7, 2025
Maintains: Overweight
Price Target: $69 → $63
Current: $29.86
Upside: +110.98%
Arcus Biosciences
Feb 18, 2025
Maintains: Overweight
Price Target: $36 → $25
Current: $8.40
Upside: +197.62%
Organon & Co.
Feb 14, 2025
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $14.72
Upside: +8.70%
CRISPR Therapeutics AG
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $40.88
Upside: -21.72%
Merck & Co.
Feb 5, 2025
Maintains: Equal-Weight
Price Target: $113 → $106
Current: $87.85
Upside: +20.66%
AbbVie
Feb 3, 2025
Maintains: Overweight
Price Target: $224 → $239
Current: $201.31
Upside: +18.72%
Nurix Therapeutics
Feb 3, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $12.59
Upside: +35.03%
Intellia Therapeutics
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $8.74
Upside: +25.86%
Jan 23, 2025
Maintains: Equal-Weight
Price Target: $175 → $163
Current: $161.04
Upside: +1.22%
Nov 12, 2024
Maintains: Underweight
Price Target: $36 → $39
Current: $59.20
Upside: -34.12%
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $30 → $31
Current: $25.55
Upside: +21.33%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $20.28
Upside: +481.85%
Aug 27, 2024
Reiterates: Overweight
Price Target: $1,106
Current: $852.34
Upside: +29.76%
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $3.99
Upside: +802.26%
Jul 11, 2024
Maintains: Overweight
Price Target: $48 → $51
Current: $33.76
Upside: +51.07%
Jul 11, 2024
Maintains: Equal-Weight
Price Target: $310 → $303
Current: $306.76
Upside: -1.23%
Jul 11, 2024
Downgrades: Equal-Weight
Price Target: $310 → $321
Current: $316.57
Upside: +1.40%
May 6, 2024
Maintains: Buy
Price Target: $121 → $168
Current: $93.15
Upside: +80.35%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.17
Upside: +268.66%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $139.18
Upside: +213.26%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $281.02
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.34
Upside: -